Glenmark Pharmaceuticals
Market cap ₹61,147 Cr
- P/E
- 34.02
- Day range
- ₹2,101.60 – ₹2,203.80
- 52-week range
- ₹1,792.60 – ₹2,537.60
- Volume
- 8.93 L
- Open
- ₹2,196.00
- Prev close
- ₹2,198.50
Latest results · Q1 FY27(consolidated)Revenue ₹4,018 Cr+23.1%Profit ₹483 Cr+927.9%Margin 12.0%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
GLENMARK in NSE indices and F&O
F&O margin for one lot of GLENMARK (375 shares)Research profile
Composite 69 / 100Factor percentiles
Derived metrics
- Earn. yield
- 2.9%
- Graham no.
- ₹954.61
- vs Graham
- -55.9%
- ROE ÷ P/B
- 2.4%
- 12-1 mom.
- +30.0%
- Return / vol
- 0.53
- Magic Formula
- #103
- Piotroski
- 5/6
- FCF yield
- 3.4%
- PEG
- 0.01
Appears in 14 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 67 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.19 L Cr | 34.68 | 5.02 | 14.8% | 21.0% | 29.0% | 0.06 | +10.5% |
| Divi's LaboratoriesDIVISLAB | ₹2.38 L Cr | 81.21 | 14.52 | 16.2% | 22.0% | 41.0% | 0.00 | +27.8% |
| Torrent PharmaTORNTPHARM | ₹1.72 L Cr | 76.43 | 9.37 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Zydus LifesciencesZYDUSLIFE | ₹1.13 L Cr | 25.17 | 4.20 | 20.1% | 21.0% | 24.0% | 0.46 | +22.0% |
| Apollo HospitalsAPOLLOHOSP | ₹1.11 L Cr | 53.19 | 11.54 | 22.6% | 17.0% | 16.0% | 0.90 | +20.6% |
| CiplaCIPLA | ₹1.08 L Cr | 32.09 | 3.12 | 11.8% | 15.0% | 17.0% | 0.02 | +2.3% |
| Laurus LabsLAURUSLABS | ₹1.06 L Cr | 97.38 | 20.06 | 18.2% | 18.0% | 32.0% | 0.48 | +29.0% |
| Glenmark PharmaceuticalsGLENMARK | ₹61,147 Cr | 34.02 | 5.91 | 14.1% | 40.0% | 20.0% | 0.06 | +23.1% |
| Sector median | ₹23,579 Cr | 41.61 | 5.60 | 15.1% | 17.0% | 25.0% | 0.16 | +20.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 7d agoHeadlines about Glenmark Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Parasram India does not endorse them.
Key metrics
- P/E (TTM)
- 19.6
- Price / Book
- 5.82
- ROE (FY26)
- 14.1%
- ROCE (latest year)
- 40%
- Dividend yield
- 0.23%
Moving averages (NSE)
- 20-day
- ₹2,282.88
- Price below
- 50-day
- ₹2,357.1
- Price below
- 200-day
- ₹2,218.13
- Price below
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- FII
- DII
- Public
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 |
| Expenses | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 |
| Operating Profit | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 |
| OPM % | 14% | -8% | 16% | 18% | 18% | 18% | 17% | 18% | 39% | 22% | 20% | 20% |
| Other Income | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 |
| Interest | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 |
| Depreciation | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 |
| Profit before tax | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 |
| Tax % | 997% | -18% | 319% | 26% | 25% | 24% | 45% | 51% | 37% | 24% | 22% | 25% |
| Net Profit | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 |
| EPS in Rs | ₹-2.90 | ₹-12.45 | ₹-43.17 | ₹12.06 | ₹12.55 | ₹12.33 | ₹0.16 | ₹1.66 | ₹21.63 | ₹14.29 | ₹10.68 | ₹17.11 |
From company filings, updated 26 Oct 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+21 days since Mar 2021
+34 days since Mar 2021
+62 days since Mar 2021
-7 days since Mar 2021
+14 days since Mar 2021
Strengths, risks & growth
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]
Strengths
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 19.4% CAGR over last 5 years
Risks
- The company has delivered a poor sales growth of 9.19% over past five years.
- Company has a low return on equity of -3.28% over last 3 years.
- Debtor days have increased from 85.2 to 107 days.
- Working capital days have increased from 41.2 days to 80.5 days
Compounded Sales Growth
- 10 Years
- +8%
- 5 Years
- +9%
- 3 Years
- +14%
- TTM
- +33%
Compounded Profit Growth
- 10 Years
- +12%
- 5 Years
- +19%
- 3 Years
- +61%
- TTM
- +134%
Stock Price CAGR
- 10 Years
- +9%
- 5 Years
- +34%
- 3 Years
- +43%
- 1 Year
- +19%
Return on Equity
- 10 Years
- +7%
- 5 Years
- +2%
- 3 Years
- -3%
- Last Year
- +24%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 46.65% | 46.65% | 46.65% | 46.65% | 0.00 pp |
| FII | 19.20% | 20.35% | 20.89% | 21.51% | +0.62 pp |
| DII | 20.09% | 19.28% | 18.60% | 17.63% | -0.97 pp |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.00 pp |
| Public | 14.02% | 13.70% | 13.81% | 14.17% | +0.36 pp |
Filed with NSE for Sept 2026: promoters 46.65%, public 53.35% · XBRL filing
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 15.61% (-1.15 pp)- Promoters46.6%
- Foreign institutions21.5%
- Mutual funds15.6%
- Insurance0.8%
- Other domestic institutions1.2%
- Retail8.0%
- Others6.2%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| HDFC Mid Cap Fund | 4.98% | 3.07% | +0.14 pp |
| Invesco India Midcap Fund | 0.69% | 2.76% | -0.22 pp |
| Invesco India Contra Fund | 0.63% | 2.06% | +0.19 pp |
| Invesco India Large & Mid Cap Fund | 0.50% | 2.57% | -0.08 pp |
| Bandhan Large & Mid Cap Fund | 0.43% | 1.31% | +0.18 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.
Risk & trend
From 275 daily sessions to 23 Oct 2026.
Risk
- Volatility (1Y)
- 27.3%
- Downside volatility
- 28.3%
- Worst 5% of days
- 3.3%
- Average of that tail
- 4.2%
- Max drawdown (1Y)
- 15.1%
- Below its peak
- 13.9%
Against the market
- Beta vs Nifty 50
- 0.88
- Correlation
- 0.43
- Relative strength (3M)
- +3.6%
- ATR (14)
- 3.1%
Return
- Return 1M
- -12.0%
- Return 3M
- -1.7%
- Return 6M
- -3.3%
- Return 1Y
- +14.5%
- vs 200-day average
- -2.3%
Momentum
- RSI (14)
- 34.2
- MACD histogram
- -10.73
- Stochastic %K
- 27.2
- ADX (14)
- 36.3
- +DI / −DI
- 6.3 / 28.4
- Money flow index
- 21.8
Participation
- Delivery (20d avg)
- 52.9%
- vs its 60-day baseline
- +4.0 pts
- Volume vs 20-day
- +0.8σ
- Close vs day's VWAP
- +1.5%
- 52-week position
- 51 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- ₹2,087 Cr
- FCF yield
- 3.4%
- Cash conversion
- 2.53
- Accruals ratio
- -0.105
- Net debt
- -₹581 Cr
- Net debt / equity
- -0.06
- EV / sales
- 3.41
- PEG
- 0.01
- Capex intensity
- 8.0%
- Revenue CAGR
- 15.8%
- Profit CAGR
- 6773.2%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹2.50
Dividend - Rs 2.50 Per Share
31 Aug 2026ex-date - dividend₹2.50
Interim Dividend - Rs 2.50 Per Share
3 Oct 2025ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
15 Sept 2025ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
13 Sept 2024ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
18 Sept 2023ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
12 Sept 2022ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
8 Sept 2021ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
17 Sept 2020ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
19 Sept 2019ex-date - dividend₹2.00
Annual General Meeting/Dividend Rs 2 Per Share
19 Sept 2018ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2/- Per Share
20 Sept 2017ex-date - dividend₹2.00
Annual General Meeting/ Dividend - Rs 2/- Per Share
3 Aug 2016ex-date - dividend₹2.00
Annual General Meeting/ Dividend - Rs 2/- Per Share
10 Sept 2015ex-date - dividend₹2.00
Annual General Meeting / Dividend - Rs 2/- Per Share
10 Jul 2014ex-date - dividend₹2.00
Annual General Meeting / Dividend - Rs 2/- Per Share
18 Jul 2013ex-date - dividend₹2.00
Annual General Meeting / Dividend Rs 2 Per Share
19 Jul 2012ex-date - dividendNot available — not reported in this filing
Annual General Meeting And Dividend Re.0.40 Per Share
28 Jul 2011ex-date - dividendNot available — not reported in this filing
Annual General Meeting And Dividend Re.0.40 Per Share
16 Sept 2010ex-date - otherNot available — not reported in this filing
Agm/Div-Re.0.40 Per Share
10 Sept 2009ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Sept 2008ex-date
Company announcements
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Intimation of Earnings Call
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)
Intimation for closure of trading window for second quarter of FY 2026-27
Glenmark Pharmaceuticals receives Establishment Inspection Report (EIS) from U.S. FDA for its Goa facility with VAI classification
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst/ Institutional Investor Meetings
Report of Scrutinizer is enclosed
Proceedings of the 48th AGM of the Company is enclosed
Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil
Please find enclosed rating rationale issued by India Ratings and Research
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")
Letter to Shareholders whose email address are not registered providing the web link of Annual Report
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
Filed with BSE (scrip 532296); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Aug 2026TranscriptSlidesRecording
- Jun 2026TranscriptSlidesRecording
- May 2026Slides
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Aug 2025TranscriptSlides
Credit ratings
- Rating update · 10 Sep from fitch
- Rating update · 12 Aug from crisil
- Rating update · 11 Feb from crisil
- Rating update · 18 Sep 2025 from crisil
- Rating update · 23 Jul 2025 from fitch
- Rating update · 18 Jun 2025 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 1 Aug 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Glenmark Pharmaceuticals: common questions
Answered from the figures on this page.
